Skip to main content

Table 2 The expression of SFRP1 versus clinical features

From: Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma

Clinicopathological parameters   Number of patients Down* regultaion No Down regultaion X 2 p
Gender       
  male 40 32 (80.2%) 8 (20.0%) 2.770 0.065
  female 6 3 (50.0%) 3 (50.0%)   
Age       
  ≥60 7 5 (71.4%) 2 (28.6%) 0.098 0.754
  <60 39 30 (76.9%) 9 (23.1%)   
Tumor Size (cm)       
  >3 cm 39 31 (45.5%) 8 (54.5%) 1.629 0.202
  ≤3 cm 7 4 (37.5%) 3 (62.5%)   
D8S532       
  LOH+ 6 5 (83.3%) 1 (16.7%) 0.361 0.548
  LOH- 40 30 (75%) 10 (25%)   
D8SAC016868       
  LOH+ 3 3 (100.0%) 0 1.30 0.254
  LOH- 43 32 (74.4%) 11 (25.6%)   
  1. *Down-regulation of SFRP1 was designed as ≤0.5 (HCC/non-HCC)